Edgewise Therapeutics (EWTX): Director sold, ~$26K

~$26K
Approx. value · 1,907 sh @ $13.39: 23K
Holds after · shares reported

Traded: Aug 12, 2025
Filed: Aug 14, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

Aug 12, 2025 · this disclosureInsiderDirector sold ~$26K of EWTX shares in the open market

What came next

Aug 12, 2025Insider · 5 peopleInsiders: 5 sales (~$226K)
Aug 26, 2025InsiderDirector sold ~$1.46M of EWTX shares in the open market
Nov 6, 2025Company filing · Form 8-K · ResultsReported its results
Nov 10, 2025Company filing · Form 8-K · Executive change, Reg FDChanged a top executive or board member, and shared information with investors“On November 10, 2025, Edgewise Therapeutics, Inc. (the “ Company ”) announced the appointment of Michael Nofi as the Company’s Chief Financial Officer, effective November 10, 2025.”
Nov 19, 2025Company filing · Form 8-K · Executive changeChanged a top executive or board member“On November 19, 2025, the Board of Directors (the “Board”) of Edgewise Therapeutics, Inc. (the “Company”) appointed Christopher Martin to serve as a Class I director, with a term expiring at the Company’s 2028 annual meeting of stockholders.”

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Edgewise Therapeutics

For Edgewise Therapeutics, OQRO holds 7 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its EWTX page.

Other recent filings by Alan J Russell, Chief Scientific Officer

The full history of Alan J Russell, Chief Scientific Officer is on the profile page.

Other disclosures at Edgewise Therapeutics

Everything OQRO holds on this company is on its EWTX page.

Edgewise Therapeutics (EWTX)Director sold ~$26K